Key facts
- SyntheX (Drug Discovery)’s last known valuation is $26.3M (Jan 2024).
- It has raised $11.6M; the latest was Later Stage VC in May 2025.
- Notable investors include SOSV, 8VC, Endless Frontier Labs, IndieBio, Augustin Ku — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for SyntheX (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for SyntheX (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SyntheX (Drug Discovery)
Developer of a proprietary drug discovery platform designed to find protein interaction disruptors, bridgers, and molecular glue degraders. The company utilizes genetically engineered circuits, technologies, and proprietary DNA-encoded peptide and macrocycle libraries that rely on intracellular drug selection as opposed to in vitro screening, enabling healthcare institutions to serve human health for the treatment of cancer and rare diseases.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2016
- Employees
- 35
- Website
- synthexlabs.com/
- Ownership
- Privately Held (backing)
SyntheX (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SyntheX (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SyntheX (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.